Related Experiment Video
Updated: Aug 16, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Children with Near-Fatal Asthma: The Use of Inhaled Volatile Anesthetics and Extracorporeal Membrane Oxygenation
Chasity M Custer1, Erika R O'Neil2, Janaki Paskaradevan3
1Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA.
Insights
Extracorporeal membrane oxygenation (ECMO) is a safe and effective treatment for near-fatal asthma. ECMO may reduce bronchodilator medication exposure compared to inhaled volatile anesthetics in severe asthma cases.
Area of Science:
- Pediatric Critical Care Medicine
- Respiratory Medicine
- Cardiopulmonary Support
Background:
- Near-fatal asthma requires advanced respiratory support when refractory to maximal medical therapy.
- Extracorporeal membrane oxygenation (ECMO) is an established option for severe respiratory failure.
- Isoflurane has been used as an alternative for severe asthma exacerbations.
Purpose of the Study:
- To compare outcomes and medication usage in pediatric patients with near-fatal asthma treated with ECMO versus isoflurane.
- To evaluate the safety and efficacy of ECMO in refractory asthma.
- To assess bronchodilator exposure in asthma patients managed with ECMO versus isoflurane.
Main Methods:
- Retrospective study of pediatric patients with asthma admitted to Texas Children's Hospital PICU from 2012-2020.
- Comparison of demographics, medication use (albuterol, terbutaline), and complications between ECMO (n=12) and isoflurane (n=8) groups.
- Analysis of patient survival to discharge and duration of bronchodilator administration.
Main Results:
- All patients in both groups survived to discharge.
- ECMO group received significantly shorter durations of albuterol (12 vs. 104 hours, P=0.0002) and terbutaline (13.3 vs. 31.5 hours, P=0.0250).
- No significant differences in complication rates were observed between the ECMO and isoflurane groups.
Conclusions:
- ECMO represents a viable and safe support strategy for pediatric patients experiencing near-fatal asthma.
- ECMO may be associated with reduced exposure to bronchodilator medications compared to inhaled volatile anesthetics in severe asthma.
- Further research may explore optimal timing and selection criteria for ECMO in refractory asthma exacerbations.
Abstract:
The use of extracorporeal membrane oxygenation (ECMO) has been described for near-fatal asthma that continues to be refractory despite maximal medical therapy. Patients admitted to the pediatric intensive care unit at Texas Children's Hospital from 2012 to 2020 with the diagnosis of asthma who were supported on ECMO or isoflurane were included in the study. Patient demographics, medication usage, and complications were compared between the case group (ECMO, n = 12) and the control group (isoflurane only, n = 8). All patients survived to discharge. ECMO patients received shorter durations of albuterol (12 versus 104 h, P = 0.0002) and terbutaline (13.3 versus 31.5 h, P = 0.0250). There were no differences in complication rates between the 2 groups. ECMO is a reasonable and safe support method for patients with near-fatal asthma and may lead to less bronchodilator medication exposure when compared with inhaled volatile anesthetic use.
Related Concept Videos
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Inhalational Anesthetics: Overview
Cardiopulmonary Resuscitation II: ACLS Airway Management
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Acute Respiratory Failure-III

